| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 523 | 2019 |
| Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised … MCJ Slagman, F Waanders, MH Hemmelder, AJ Woittiez, WMT Janssen, ... Bmj 343, 2011 | 342 | 2011 |
| Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus … Y Miao, SA Ottenbros, GD Laverman, BM Brenner, ME Cooper, ... Hypertension 58 (1), 2-7, 2011 | 231 | 2011 |
| Vitamin K intake and status are low in hemodialysis patients ECM Cranenburg, LJ Schurgers, HH Uiterwijk, JWJ Beulens, ... Kidney international 82 (5), 605-610, 2012 | 227 | 2012 |
| Dual renin-angiotensin system blockade at optimal doses for proteinuria GD Laverman, G Navis, RH Henning, PE De Jong, D De Zeeuw Kidney international 62 (3), 1020-1025, 2002 | 220 | 2002 |
| Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial DZI Cherney, CCJ Dekkers, SJ Barbour, D Cattran, AHA Gafor, ... The lancet Diabetes & endocrinology 8 (7), 582-593, 2020 | 210 | 2020 |
| Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational … N Tofte, M Lindhardt, K Adamova, SJL Bakker, J Beige, JWJ Beulens, ... The lancet Diabetes & endocrinology 8 (4), 301-312, 2020 | 207 | 2020 |
| Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined … FA Holtkamp, D de Zeeuw, PA de Graeff, GD Laverman, T Berl, ... European heart journal 32 (12), 1493-1499, 2011 | 162 | 2011 |
| The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors? AC Hesp, JA Schaub, PV Prasad, V Vallon, GD Laverman, P Bjornstad, ... Kidney international 98 (3), 579-589, 2020 | 151 | 2020 |
| Benefits of dietary sodium restriction in the management of chronic kidney disease JA Krikken, GD Laverman, G Navis Current opinion in nephrology and hypertension 18 (6), 531-538, 2009 | 144 | 2009 |
| Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial AJ Kwakernaak, JA Krikken, SH Binnenmars, FW Visser, MH Hemmelder, ... The Lancet Diabetes & Endocrinology 2 (5), 385-395, 2014 | 121 | 2014 |
| Vitamin k intake and plasma desphospho-uncarboxylated matrix Gla-protein levels in kidney transplant recipients PY Boxma, E van den Berg, JM Geleijnse, GD Laverman, LJ Schurgers, ... PloS one 7 (10), e47991, 2012 | 108 | 2012 |
| Effects of dapagliflozin on volume status when added to renin–angiotensin system inhibitors MK Eickhoff, CCJ Dekkers, BJ Kramers, GD Laverman, M Frimodt-Møller, ... Journal of clinical medicine 8 (6), 779, 2019 | 94 | 2019 |
| Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria GD Laverman, RH Henning, PE de Jong, G Navis, D de Zeeuw American journal of kidney diseases 38 (6), 1381-1384, 2001 | 69 | 2001 |
| ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? GD Laverman, G Remuzzi, P Ruggenenti Journal of the American Society of Nephrology 15 (1_suppl), S64-S70, 2004 | 65 | 2004 |
| Inter‐individual differences in anti‐proteinuric response to ACEi in established adriamycin nephrotic rats are predicted by pretreatment renal damage AB Kramer, GD Laverman, H van Goor, G Navis The Journal of Pathology: A Journal of the Pathological Society of Great …, 2003 | 65 | 2003 |
| Proprotein convertase subtilisin–kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment AJ Kwakernaak, G Lambert, MCJ Slagman, F Waanders, GD Laverman, ... Atherosclerosis 226 (2), 459-465, 2013 | 63 | 2013 |
| Vascular endothelial growth factor C levels are modulated by dietary salt intake in proteinuric chronic kidney disease patients and in healthy subjects MCJ Slagman, AJ Kwakernaak, S Yazdani, GD Laverman, J van den Born, ... Nephrology Dialysis Transplantation 27 (3), 978-982, 2012 | 63 | 2012 |
| A self-management approach for dietary sodium restriction in patients with CKD: a randomized controlled trial JK Humalda, G Klaassen, H de Vries, Y Meuleman, LC Verschuur, ... American Journal of Kidney Diseases 75 (6), 847-856, 2020 | 57 | 2020 |
| Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes S Mulder, HJL Heerspink, M Darshi, JJ Kim, GD Laverman, K Sharma, ... Diabetes, Obesity and Metabolism 21 (11), 2422-2428, 2019 | 57 | 2019 |
